Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

564

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Functional Dyspepsia
Interventions
DRUG

Itopride Hydrochloride 150 mg extended release tablets

"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"

DRUG

Itopride Hydrochloride 50 mg film coated tablets

"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"

Trial Locations (19)

2000

GreenCity Medical Center, Pampanga

6000

Cebu Doctors University Hospital, Cebu City

8000

Davao Doctors Hospital, Davao City

10400

Phramongkulklao Hospital, Bangkok

13300

King Chulalongkorn Memorial, Bangkok

40002

Srinagarind Hospital, Khon Kaen

50200

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

70000

Nguyen Tri Phuong Hospital, Ho Chi Minh City

Unknown

"Grigor Narekatsi MC, CJSC", Yerevan

"Hera Med LLC (Medicus Medical Center)", Yerevan

"Institute of Surgery Mickaelyan CJSC", Yerevan

Polyclinic N 12 Health State, CJSC, Yerevan

Hospital Sultanah Bahiyah, Alor Star

Queen Elizabeth Hospital, Kota Kinabalu

Pantai Hospital Kuala Lumpur, Kuala Lumpur

UMMC, Petaling Jaya

Health Cube Medical Clinics, Manila

103 Military Hospital, Hanoi

Bach Mai Hospital, Hanoi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT06217393 - Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia | Biotech Hunter | Biotech Hunter